Low Dose Monacolin K Combined with Coenzyme Q10, Grape Seed, and Olive Leaf Extracts Lowers LDL Cholesterol in Patients with Mild Dyslipidemia: A Multicenter, Randomized Controlled Trial

source extracted confidence: high 2026-04-09
#humans #lovastatin #cholesterol-ldl #hypercholesterolemia #olea

Low Dose Monacolin K Combined with Coenzyme Q10, Grape Seed, and Olive Leaf Extracts Lowers LDL Cholesterol in Patients with Mild Dyslipidemia: A Multicenter, Randomized Controlled Trial

Angelopoulos et al., 2023 | Nutrients | Rct

Citation

Angelopoulos Nicholas, Paparodis Rodis D, ... Livadas Sarantis. Low Dose Monacolin K Combined with Coenzyme Q10, Grape Seed, and Olive Leaf Extracts Lowers LDL Cholesterol in Patients with Mild Dyslipidemia: A Multicenter, Randomized Controlled Trial. Nutrients. 2023-Jun-09;15(12). doi:10.3390/nu15122682

Abstract

Certain nutraceuticals, mainly containing red yeast rice, might be considered as an alternative therapy to statins in patients with dyslipidemia, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. The aim of this study was to assess the lipid-lowering activity and safety of a dietary supplement containing a low dose of monacolin K combined with coenzyme Q10, grape seed and olive tree leaf extracts in patients with mild hypercholesterolemia. In total, 105 subjects with mild hypercholesterolemia (low-density lipoprotein cholesterol LDL-C levels 140-180 mg/dL) and low CV risk were randomly assigned into three treatment groups: lifestyle modification (LM), LM plus a low dosage of monacolin K (3 mg), and LM plus a high dosage of monacolin K (10 mg) and treated for 8 weeks. The primary endpoint was the reduction of LDL-C and total cholesterol (TC). LDL-C decreased by 26.46% on average (p < 0.001) during treatment with 10 mg of monacolin and by 16.77% on average during treatment with 3 mg of monacolin (p < 0.001). We observed a slight but significant reduction of the triglyceride levels only in the high-dose-treated group (mean -4.25%; 95% CI of mean -11.11 to 2.61). No severe adverse events occurred during the study. Our results confirm the LDL-C-lowering properties of monacolin are clinically meaningful even in lower doses of 3 mg/day.

Key Findings

Our results confirm the LDL-C-lowering properties of monacolin are clinically meaningful even in lower doses of 3 mg/day.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population dyslipidemia
Sample Size 105
Age Range See abstract
Condition See abstract

MeSH Terms

  • Humans
  • Lovastatin
  • Cholesterol, LDL
  • Hypercholesterolemia
  • Olea
  • Vitis
  • Dyslipidemias
  • Dietary Supplements
  • Anticholesteremic Agents
  • Ubiquinone

Evidence Classification

  • Level: Rct
  • Publication Types: Randomized Controlled Trial, Multicenter Study, Journal Article
  • Vertical: red-yeast-rice

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09